These are integrated National Guidelines 2013 for Prevention and Management of HIV, STIs & Other Blood Borne Infections in accordance with the last guidelines of the World Health Organization (WHO) published in June 2013 and adapted to the Rwandan national context. It thus responds to the need by th...e Ministry of Health to improve skills of actors in the health sector as well as the quality of care and treatment offered in both public and private health facilities countrywide.
more
This manual describes methods for investigating clusters or outbreaks that may be of chemical origin and describes the importance of a structured, coordinated, collaborative multidisciplinary, multi-agency approach at local, regional, national and international levels.
Guidelines for Diagnosis and Management of Lung Cancer in Indonesia
Recommendations for a public health approach
2010 revision
El objetivo de esta GPC es proporcionar recomendaciones para el tamizaje organizado
del CCR en el territorio nacional, permitiendo el acceso equitativo a medidas de
prevención y detección temprana de la enfermedad con el fin de disminuir la
incidencia y la mortalidad por el CCR en Argentina.... Esta guía está destinada a todos
aquellos trabajadores de la salud que desarrollen actividades de prevención del CCR.
La población objetivo incluye a aquellos individuos de riesgo promedio, sin
antecedentes personales ni familiares de CCR ni adenomas. Sin embargo, aquellos
individuos identificados con presencia de síntomas sospechosos de CCR, individuos
con incremento del riesgo para el desarrollo de esta enfermedad (síndrome de Lynch,
PAF, PAFA, poliposis hamartomatosas, síndrome de poliposis aserrada, EII, etc.) o con
antecedentes de resecciones de pólipos o adenomas, deberán ser priorizados en el
seguimiento o derivados a atención especializada consecuente, según las
recomendaciones vigentes.
more
Participant Manual September 2009
The 23rd meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was coordinated from Geneva, Switzerland, and held virtually from 21 June to 2 July 2021. The Committee considered 88 applications proposing additions, changes and deletions of medicines, medicine classes and fo...rmulations on the Model Lists of Essential Medicines. The Committee evaluated the scientific evidence for comparative effectiveness, safety and cost-effectiveness of the medicines in question. The Committee also considered a review of the therapeutic alternatives for medicines on the Model Lists, and update to the AWaRe classification of antibiotics, and reviews and reports relevant to the selection and use of essential medicines.
more
Developmental disorders
Chapter C.2
2014 Edition
The Access to Controlled Medications Programme identified the development of treatment guidelines that cover the treatment of all types of pain as one of the core areas of focus for improving access to opioid analgesics. Such guidelines are interesting both for health-care professionals and policy-...makers. They are also important in improving access to controlled medicines for determining when those opioid medicines and when non-opioid medicines are preferred.
Based on a Delphi study, WHO planned the development of three treatment guidelines, covering chronic pain in children, chronic pain in adults and acute pain.
more
Integrated Management of Adolescent and Adult Illness (IMAI)
July 2008
Report of the 23rd WHO Expert Committee on the selection and use of essential medicines
This executive summary reports the recommendations made by the Expert Committee for the 2021 update of the WHO Model List of Essential Medicines (EML) and the Model List of Essential Medicine for Children (EMLc)....
The 23rd meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was coordinated from Geneva, Switzerland, and held virtually from 21 June to 2 July 2021. The Committee considered 88 applications proposing additions, changes and deletions of medicines, medicine classes and formulation on the Model Lists of Essential Medicines. The Committee evaluated the scientific evidence for comparative effectiveness, safety and cost-effectiveness of the medicines in question. The Committee also considered a review of the therapeutic alternatives for medicines on the Model Lists, and update to the AWaRe classification of antibiotics, and reviews and reports relevant to the selection and use of essential medicines.
more